MapLight Therapeutics, Inc. (MPLT)
9.82
+0.19
(+1.97%)
USD |
NASDAQ |
Oct 02, 16:00
9.82
0.00 (0.00%)
Pre-Market: 08:00
MapLight Therapeutics Enterprise Value : 143.45M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 143.45M |
| October 01, 2026 | 134.82M |
| September 30, 2026 | 160.26M |
| September 29, 2026 | 158.45M |
| September 28, 2026 | 172.08M |
| September 25, 2026 | 172.53M |
| September 24, 2026 | 186.16M |
| September 23, 2026 | 186.62M |
| September 22, 2026 | 190.71M |
| September 21, 2026 | 192.52M |
| September 18, 2026 | 193.43M |
| September 17, 2026 | 211.61M |
| September 16, 2026 | 215.24M |
| September 15, 2026 | 246.14M |
| September 14, 2026 | 294.76M |
| September 11, 2026 | 287.94M |
| September 10, 2026 | 323.61M |
| September 09, 2026 | 320.20M |
| September 08, 2026 | 331.11M |
| September 04, 2026 | 322.93M |
| September 03, 2026 | 294.30M |
| September 02, 2026 | 290.67M |
| September 01, 2026 | 302.03M |
| August 31, 2026 | 286.58M |
| August 28, 2026 | 269.77M |
| Date | Value |
|---|---|
| August 27, 2026 | 267.04M |
| August 26, 2026 | 281.58M |
| August 25, 2026 | 267.04M |
| August 24, 2026 | 213.43M |
| August 21, 2026 | 206.61M |
| August 20, 2026 | 207.52M |
| August 19, 2026 | 249.32M |
| August 18, 2026 | 234.33M |
| August 17, 2026 | 208.20M |
| August 14, 2026 | 231.15M |
| August 13, 2026 | 223.42M |
| August 12, 2026 | 214.33M |
| August 11, 2026 | 241.60M |
| August 10, 2026 | 250.68M |
| August 07, 2026 | 250.23M |
| August 06, 2026 | 300.66M |
| August 05, 2026 | 284.31M |
| August 04, 2026 | 285.22M |
| August 03, 2026 | 267.50M |
| July 31, 2026 | 288.85M |
| July 30, 2026 | 334.74M |
| July 29, 2026 | 379.72M |
| July 28, 2026 | 256.59M |
| July 27, 2026 | 147.31M |
| July 24, 2026 | 1.358B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics, Inc. | 2.106B |
| Cullinan Therapeutics, Inc. | 668.70M |
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Oncolytics Biotech, Inc. | 74.98M |
| Sangamo Therapeutics, Inc. | 52.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.19M |
| Total Expenses (Quarterly) | 60.19M |
| EPS Diluted (Quarterly) | -1.325 |
| Earnings Yield | -52.16% |
| Normalized Earnings Yield | -52.16 |